STOCK TITAN
  1. Home
  2. Sec-filings
  3. KTTA
  4. [Form 4] Pasithea Therapeutics Corp. Insider Trading Activity

Coastlands Capital LP (KTTA) adds 100,000 Pasithea Therapeutics shares in open-market buy

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Pasithea Therapeutics Corp. insider Coastlands Capital LP reported an open-market purchase of 100,000 shares of common stock at $0.53 per share. After this transaction, Coastlands Capital LP is shown as indirectly owning 3,835,035 common shares through its investment partnership structure.

The filing notes that Coastlands Capital LP, its related general partners and control person Matthew Perry are reporting jointly and each disclaims beneficial ownership of the common stock beyond any pecuniary interest. Coastlands Capital LP is identified as a more than ten percent owner of Pasithea Therapeutics.

Positive

  • None.

Negative

  • None.
Insider Coastlands Capital LP
Role null
Bought 100,000 shs ($53K)
Type Security Shares Price Value
Purchase Common Stock 100,000 $0.53 $53K
Holdings After Transaction: Common Stock — 3,835,035 shares (Indirect, By Coastlands Capital LP)
Footnotes (1)
  1. [object Object]
Shares purchased 100,000 shares Open-market purchase on 2026-06-17
Purchase price $0.53 per share Price for Pasithea common stock
Total shares after transaction 3,835,035 shares Indirect holdings following purchase
Net share change 100,000 shares Net buy direction in this Form 4
open-market purchase financial
"transaction_action: open-market purchase"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
beneficial ownership regulatory
"Each reporting person also disclaims beneficial ownership of common stock"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of that person's pecuniary interest therein"
more than ten percent owner regulatory
"is_ten_percent_owner: 1"
indirect ownership financial
"ownership_type: indirect; nature_of_ownership: By Coastlands Capital LP"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Coastlands Capital LP
(Last)(First)(Middle)
601 CALIFORNIA STREET
SUITE 1210
(Street)
SAN FRANCISCO CALIFORNIA 94108
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Pasithea Therapeutics Corp. [ KTTA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/17/2026P100,000A$0.533,835,035IBy Coastlands Capital LP(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.
/s/ Mark Shamia, Chief Operating Officer of the General Partner of Coastlands Capital LP06/22/2026
/s/ Mark Shamia, Chief Operating Officer of the General Partner of Coastlands Capital Partners LP06/22/2026
/s/ Mark Shamia, Chief Operating Officer of Coastlands Capital GP LLC06/22/2026
/s/ Mark Shamia, Chief Operating Officer of Coastlands Capital LLC06/22/2026
/s/ Matthew D. Perry06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Coastlands Capital LP report in Pasithea Therapeutics (KTTA)?

Coastlands Capital LP reported buying 100,000 shares of Pasithea Therapeutics common stock in an open-market transaction at $0.53 per share. This Form 4 filing reflects an increase in its indirectly held position in the company’s equity.

At what price did Coastlands Capital LP buy KTTA shares in this Form 4?

The reported purchase price was $0.53 per Pasithea Therapeutics common share. The transaction involved 100,000 shares, indicating a total cash outlay of $53,000 based on the disclosed per-share price in the open-market purchase.

How many Pasithea Therapeutics (KTTA) shares does Coastlands Capital LP hold after this transaction?

Following the reported transaction, Coastlands Capital LP indirectly holds 3,835,035 shares of Pasithea Therapeutics common stock. The ownership is reported as indirect, reflecting the firm’s role as investment adviser to a partnership that holds the shares.

Is Coastlands Capital LP considered a major shareholder of Pasithea Therapeutics (KTTA)?

Yes. The Form 4 identifies Coastlands Capital LP as a more than ten percent owner of Pasithea Therapeutics. This status classifies the firm as an insider under SEC rules, requiring public reporting of its transactions in the company’s equity securities.

How is Coastlands Capital LP’s ownership of KTTA structured according to the filing footnote?

The filing explains that Coastlands Capital LP and related general partners advise and manage a Delaware limited partnership that holds the shares. The reporting persons jointly file but each disclaims beneficial ownership beyond their pecuniary interest in Pasithea Therapeutics stock.

Was the KTTA insider transaction by Coastlands Capital LP a buy or a sell?

The transaction was a buy. Coastlands Capital LP executed an open-market purchase of 100,000 Pasithea Therapeutics common shares. The transaction code is “P,” and the filing classifies it as an open-market purchase rather than a sale or derivative exercise.